scholarly journals Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

2020 ◽  
Author(s):  
Alexander Schwickert ◽  
Frédéric Chantraine ◽  
Loreen Ehrlich ◽  
Wolfgang Henrich ◽  
Mustafa Zelal Muallem ◽  
...  
Keyword(s):  
Case Control Study ◽  
Predictive Biomarker ◽  
Serum Levels ◽  
Case Control ◽  
Maternal Serum ◽  
Control Group ◽  
Serum Samples ◽  
Invasive Placenta ◽  
Control Study ◽  
Abnormally Invasive Placenta

Abstract The aim of this study was to test if maternal serum vascular endothelial growth factor (VEGF) or N-terminal pro B-type natriuretic peptide (NT-proBNP) predicts abnormally invasive placenta (AIP) better. Secondary objective was to test whether the serum levels of VEGF and NT-proBNP can predict the degree of invasion. In a multicenter case–control study design, gestational age-matched serum samples from pregnant women with AIP (n = 44) and uncomplicated pregnancies (n = 55) who had been enrolled at Charité – Universitätsmedizin Berlin, Germany and Centre Hospitalier Régional de la Citadelle in Liège, Belgium were analyzed. Maternal blood serum VEGF and NT-proBNP levels were immunoassayed from samples taken immediately before delivery (GA median: 35 weeks). Biomarker levels were compared between AIP and control group. The correlation of biomarker levels with the clinical AIP degree was assessed. The predictive biomarker ability was characterized through a multivariate regression model and receiver operating characteristic curves. Women with AIP had significantly lower maternal serum VEGF levels (AIP mean 285 pg/ml, 95% CI 248–322, vs. control: 391 pg/ml, 95% CI 356–426, p < 0.01) and higher NT-proBNP levels (AIP median 329 pg/ml, IQR 287–385, vs. control 295 pg/ml, IQR 273–356, p = 0.03). Maternal serum VEGF levels were able to predict AIP better (AUC = 0.729, 0.622–0.836, p < 0.001; VEGF + number of previous cesarean deliveries: AUC = 0.915, 0.853–0.977, p < 0.001). Maternal serum VEGF levels correlated inversely with the clinical AIP degree (r = − 0.32, p < 0.01). In short, maternal serum VEGF, more than NT-proBNP, can help in predicting AIP and hints at the degree of invasion.

Serum otolin-1 as a biomarker for benign paroxysmal positional vertigo: a case-control study

2021 ◽  
pp. 1-4
Author(s):  
D V K Irugu ◽  
A Singh ◽  
H Yadav ◽  
H Verma ◽  
R Kumar ◽  
...  
Keyword(s):  
Serum Level ◽  
Benign Paroxysmal Positional Vertigo ◽  
Case Control Study ◽  
Serum Levels ◽  
Case Control ◽  
Control Group ◽  
Positional Vertigo ◽  
The Difference ◽  
Control Study ◽  
Paroxysmal Positional Vertigo

Abstract Objectives This study aimed to evaluate serum otolin-1 levels in patients with benign paroxysmal positional vertigo and to compare these levels with healthy individuals. Method This was a case-control study. After obtaining institutional ethical committee clearance, the serum level of otolin-1 was calculated in adult individuals (18–75 years old) who were divided into group 1 (patients presenting with benign paroxysmal positional vertigo) and group 2 (healthy patients without benign paroxysmal positional vertigo as the control group). Data analysis was carried out to compare the serum levels in the cases and controls. A p-value less than 0.05 was considered significant. Results A total of 70 age-matched individuals (cases, n = 40; controls, n = 30) were included in the study. The mean serum level of otolin-1 was 636.8 pg/ml (range, 259–981 pg/ml) in the group of patients with benign paroxysmal positional vertigo and 236.2 pg/ml (range, 189–370 pg/ml) in the control group. The difference was statistically significant (p = 0.0000). Conclusion The serum levels of otolin-1 in patients with benign paroxysmal positional vertigo are significantly higher compared with individuals without benign paroxysmal positional vertigo.

scholarly journals Interleukin-15 (IL-15) and Anti-C1q Antibodies as Serum Biomarkers for Ectopic Pregnancy and Missed Abortion

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Alexandros Daponte ◽  
Efthimios Deligeoroglou ◽  
Spyros Pournaras ◽  
Christos Hadjichristodoulou ◽  
Antonios Garas ◽  
...  
Keyword(s):  
Ectopic Pregnancy ◽  
Case Control Study ◽  
Statistical Significance ◽  
Serum Levels ◽  
Case Control ◽  
Maternal Serum ◽  
Missed Abortion ◽  
Interleukin 15 ◽  
Immunological Factors ◽  
Control Study

Given the present lack of clinically useful tests for the accurate diagnosis of ectopic pregnancy (EP), there is a need to select out those immunological factors measured in the maternal serum, as potential biomarkers. Our assumption was that C1q/anti-C1q antibody complexes and serum levels of interleukin-15 (IL-15) may play a role in differentiating abortions (MAs) and EPs and normal pregnancies. We assessed whether their measurement could set the diagnosis in a case control study at 6–8 weeks consisting of 60 women with failed early pregnancy (30 EPs, 30 MAs) and 33 women with intrauterine pregnancies. Normal pregnancies contain anti-C1q antibodies more frequently compared to women with failed pregnancies, the lowest levels being found in EPs, but this lacked statistical significance and anti-C1q could not serve as a marker. However EP pregnancies had elevated IL-15 levels that could statistically significantly differentiate them from MAs and IUPs. Furthermore, when assessing IL-15 for the clinically important differentiation between IUP and EP, we found at a cut-off of 16 pg/mL a negative predictive value of 99 with a sensitivity for diagnosing an EP of 92%. According to these results, serum IL-15 is a promising marker differentiating an MA from an EP.

scholarly journals Mannose-binding lectin serum levels and (Gly54asp) gene polymorphism in recurrent aphthous stomatitis: A case-control study

2021 ◽  
Vol 35 ◽  
pp. 205873842110644
Author(s):  
Shereen A Baioumy ◽  
Shaimaa H Fouad ◽  
Shaimaa A Abdalgeleel ◽  
Ahmed A Baiomy ◽  
Dina E Sallam ◽  
...  
Keyword(s):  
Case Control Study ◽  
Serum Levels ◽  
Case Control ◽  
Recurrent Aphthous Stomatitis ◽  
Mannose Binding Lectin ◽  
Aphthous Stomatitis ◽  
Control Group ◽  
Mannose Binding ◽  
Binding Lectin ◽  
Control Study

Objectives: Dysregulation of the immune response appears to play a significant role in recurrent aphthous stomatitis (RAS) development. The main objective of this case–control study is to investigate the blood levels of mannose-binding lectin (MBL) and the frequency of the MBL2 gene (gly54asp) polymorphism in RAS patients, including 40 RAS patients and 40 healthy controls. Methods: Serum MBL levels were determined by ELISA, while the PCR-restriction fragment length polymorphism was used in MBL2 genotyping. Results: The median serum MBL level was significantly lower in the RAS group than in the control group (975 ng/mL (545–1320) vs. 1760 ng/mL (1254–2134); p≤ 0.001). The MBL levels were significantly lower in the BB genotype, whereas they were significantly higher in the wild type AA with a median of 525 and 1340 ng/mL, respectively ( p =0.005). The B allele was expressed in significantly higher percentages of RAS patients than in controls. There was no significant association between MBL serum levels ( p=0.685) or MBL2 codon 54 genotypes ( p=0.382) with the type of ulcers. Conclusion: There was an association between low MBL serum levels and the variant allele B of the MBL2 (gly54asp) gene, and the susceptibility to RAS. As a result, potential novel therapeutic options for RAS patients with MBL deficiency should be investigated.

scholarly journals The Role of Toxoplasma gondii Infection Among Multiple Sclerosis Patient Compared to Ordinary People in South of Iran: A Case-Control Study

2020 ◽  
Vol 17 (3) ◽  
Author(s):  
Mahsa Rahnama ◽  
Qasem Asgari ◽  
Peiman Petramfar ◽  
Davod Tasa ◽  
Vahid Hemati ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Toxoplasma Gondii ◽  
Case Control Study ◽  
Case Control ◽  
Control Group ◽  
Ordinary People ◽  
Serum Samples ◽  
Significant Difference ◽  
Control Study

Background: Toxoplasmosis is a common parasitic disease, which leads to serious disease symptoms in immunocompromised hosts and infants. Recent epidemiologic surveys showed that microbial agents may be associated with some cases of multiple sclerosis (MS). Objectives: This case-control study aimed to examine the role of Toxoplasma gondii in MS by evaluating sero-frequency of anti-T. gondii IgG (ATXAb) antibody between patients with MS and ordinary people in Shiraz Province, south of Iran during 2016 - 2018. Methods: Serum samples obtained from MS patients (n = 130), and a group of age and gender-matched controls (n = 130) with the same socioeconomic status with the patients’ group were collected to evaluate the prevalence of T. gondii IgG antibodies (ATXAb). Moreover, the presence of the ATXAb antibody of the patients and controls was determined by the ELISA test. SPSS 20 software was used to perform the statistical analysis (SPSS, inc., Chicago, USA). Results: Out of 130 (35.4%) cases with MS and 130 (13.8%) controls, 46 and 18 subjects were seropositive for ATXAb, respectively. Based on the chi-square test, a significant difference was observed in terms of the positivity rates of ATXAb between the MS patient group and the control group (P = 0.001). The mean ± standard deviation ATXAb levels in controls and MS patients were found to be 61 ± 34 and 114 ± 47 IU/mL, respectively. Also, there were statistically significant differences between the levels of these two groups (P = 0.001). Conclusions: Given the relationship between toxoplasmosis and MS, it is possible that the prevalence of MS decreases by increasing hygiene and preventing toxoplasmosis.

scholarly journals Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study

2018 ◽  
Vol 27 (2) ◽  
pp. 119-125 ◽  
Author(s):  
Rosa Rosania ◽  
Ulrike Von Arnim ◽  
Alexander Link ◽  
Mirjana Rajilic-Stojanovic ◽  
Caspar Franck ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Reports ◽  
Eradication Therapy ◽  
Case Control ◽  
Control Group ◽  
Serum Samples ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
H Pylori ◽  
Control Study

Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD.Methods: IBD outpatients with both Crohn´s disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded.Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p<0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16).Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD.Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.

scholarly journals Association Between Serum C- Reactive Protein With Migraine: A Case Control Study

2015 ◽  
Vol 31 (1) ◽  
pp. 1-8
Author(s):  
Md Abdul Alim ◽  
MA Hannan ◽  
SK Abdul Kader ◽  
Abu Jafor Md Salauddin ◽  
- Kabiruzzaman ◽  
...  
Keyword(s):  
Serum Level ◽  
Case Control Study ◽  
Statistical Tests ◽  
Smoking Habit ◽  
Serum Levels ◽  
Case Control ◽  
Control Group ◽  
Headache Clinic ◽  
And Control ◽  
Control Study

Objective: The present case-control study was undertaken to find the association between serum level of CRP and attack of migraine. Methods: The study was carried out at the Headache Clinic and Outpatient Department of Neurology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka over a period of 2 years from January 2010 to December 2011. Migraine patients attending at the above mentioned places were enrolled as cases, while apparently healthy attendants of cases and other healthy persons, who did not have any history of migraine, were included as control. Based on predefined enrollment criteria, a total of 163 subjects were included in the study. Of them 87 were cases and 76 were controls. The serum levels of CRP of both cases and controls were measured and a serum level of > 6 mg/L was considered as raised/ elevated CRP. Levels of CRP were compared between groups (case and control) using appropriate statistical tests. Result: The findings of the study showed that the age and sex distribution of case and control groups were almost comparable. The behavioral factors like food or smoking habit and tobacco leaf chewing had no difference between the groups. Over 20% of migraine patients had abnormally high CRP as compared to 7.9% in the control group (p = 0.021). The migraine patients were 3(95% CI = 1.1 - 8.1) times more likely to be associated with raised CRP (> 6 mg/L) than their healthy counterparts. There were 7 migraine patients with aura and 80 without aura. The level of CRP was not found to be associated with type of migraine (with or without aura) (p = 0.960). Conclusion: Every one in five patients exhibits abnormally high CRP. The level of CRP does not vary whether the migraine is being associated with or without aura. The migraineurs carry higher risk of developing elevated CRP than their normal counterparts. Bangladesh Journal of Neuroscience 2015; Vol. 31 (1): 1-8

scholarly journals Per- and Polyfluoroalkyl Substances in Early Pregnancy and Risk for Preeclampsia: A Case-Control Study in Southern Sweden

Toxics ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 43
Author(s):  
Lars Rylander ◽  
Christian H. Lindh ◽  
Stefan R. Hansson ◽  
Karin Broberg ◽  
Karin Källén
Keyword(s):  
Early Pregnancy ◽  
Case Control Study ◽  
Case Control ◽  
Maternal Serum ◽  
Serum Concentrations ◽  
Southern Sweden ◽  
Serum Samples ◽  
Polyfluoroalkyl Substances ◽  
Low Exposure ◽  
Control Study

Preeclampsia is one of the most common causes of perinatal and maternal morbidity/mortality. One suggested environmental risk factor is exposure to endocrine-disrupting pollutants such as per- and polyfluoroalkyl substances (PFAS). The present case-control study in southern Sweden aims to investigate the hypothesized association between serum concentrations of PFAS in early pregnancy and the risk of developing preeclampsia. The study included 296 women diagnosed with preeclampsia (cases) and 580 healthy pregnant women (controls). Maternal serum samples were obtained from a biobank of samples collected in early pregnancy in connection with screening for infections. Serum concentrations of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoic acid (PFNA), and perfluorohexane sulfonate (PFHxS) were analyzed using liquid chromatography-tandem-mass-spectrometry (LC/MS/MS). Among primiparous women, there were no differences in PFAS concentrations in early pregnancy between the cases and the controls whereas among multipara women, the cases had significantly higher concentrations of PFNA (median concentrations were 0.44 and 0.38 ng/mL, p = 0.04). When individual PFAS were categorized into quartiles and adjustment for potential confounders was performed, the women in the highest quartiles had no significant increased risks of developing preeclampsia as compared with women in the lowest category. In conclusion, the present study provides limited support for the hypothesized association between PFAS and preeclampsia in a population with relatively low exposure levels.

Evaluation of the Diagnostic Properties of Serum hsa-miR-223-5p in the Detection of Gastric Cancer: A Case-Control Study

2020 ◽  
Vol 20 (7) ◽  
pp. 800-808 ◽  
Author(s):  
Amir H. Aalami ◽  
Vahid Pouresmaeil ◽  
Amir Amirabadi ◽  
Fatemeh H. Mojahed ◽  
Mahdi Q. Rad ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Case Control Study ◽  
Tumor Staging ◽  
Serum Levels ◽  
Case Control ◽  
Control Group ◽  
High Stage ◽  
Maximal Sensitivity ◽  
And Gender ◽  
Control Study

Background: MicroRNAs (miRs) are a group of small non-coding and single-stranded RNAs of 18 to 25 nucleotides. The study of microRNAs is one of the new ways to detect cancer. In this study, the serum expression of miR-223 in patients with GC was measured and compared with the control group. Methods: This case-control study was conducted on 39 patients with GC and 39 control subjects who visited the Reza Radiotherapy and Oncology Center, Mashhad, Iran, due to gastrointestinal complaints. The demographic information was collected, and the serum levels of miR-223 were measured using the real-time PCR technique in all study subjects. The association between the GC of miR-223 and tumor staging and cancer progression was assessed. Results: The miR-223 expression in GC patients was 3.10-fold higher than that of the control group (p<0.0001). The miR-223 expression was significantly higher in the GC stages and grades compared to the control group (p<0.0001 each). However, there was no significant effect for age, smoking, and gender on miR- 223 expression in GC and controls. At the optimal cutoff value of 0.7436, the maximal sensitivity of 89.74% and specificity of 84.62% were achieved for miR-223 (p<0.001). The sensitivity and specificity for miR-223 for differentiating low grades from high grade were 92.31% and 73.08% (p=0.0003), and for differentiating low stages from the high stage was 81.82% and 39.29% respectively (p=0.696). Conclusion: This study revealed that miR-223 could be considered as a non-invasive diagnostic marker in the early diagnosis of GC.

Sign in / Sign up

Export Citation Format

Share Document